Sony Corporation Acquires Film Rights to Snowden Story; Piper Jaffray Upgrades MannKind Corp. to “Neutral”

Follow this company

Companies Mentioned

05/15/2014 [ACCESSWIRE]

General Electric Company (NYSE: GE) - For an in-depth report on General Electric Company follow:

Shares of General Electric Company closed down 0.59% on Wednesday with about 20.7 million shares traded. The stock was one of the most active stocks on the NYSE. The company recently announced the launch of a new versatile computing platform, which aims to deliver improved performance, lower costs and reduced development time for military and commercial aviation customers. The platform has been developed in collaboration with GE Intelligent Platforms.

Sony Corporation (NYSE: SNE) - For an in-depth report on Sony Corporation follow:

Shares of Sony Corporation closed down 6.46% on about 7.1 million shares traded. The stock was one of the biggest decliners on the NYSE. The company announced that it has acquired the film rights to Mr. Greenwald’s book, “No Place to Hide: Edward Snowden, the NSA and the U. S. Surveillance State,” for the producers Michael G. Wilson and Barbara Broccoli.

MannKind Corp. (NASDAQ: MNKD) - For an in-depth report on MannKind Corp. follow:

MannKind Corp. shares closed up 6.53% on about 16.4 million shares traded. The stock was one of the biggest gainers on the NASDAQ. Piper Jaffray upgraded the stock to "neutral" from "underweight" and set a $6.50 price target on it. The firm noted the company had a positive FDA panel and the valuation is more attractive ahead of the July 15 Prescription Drug User Fee Act date.

Elite Pharmaceuticals, Inc. (OTCBB: ELTP) - For an in-depth report on Elite Pharmaceuticals, Inc. follow:

Shares of Elite Pharmaceuticals closed up 13.41% on about 2 million shares traded on Wednesday. The stock was one of the biggest gainers in the OTCBB market. The company had no significant news but last month announced the issuance of U.S. Patent No. 8,703,186 titled "Abuse-Resistant Oral Dosage Forms and Method of Use Thereof". This patent expands the intellectual property for the Company's opioid abuse deterrent technology. Elite now has three US patents and one Canadian patent issued in this area with additional patents pending in the U.S., Canada and Europe. 


Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures. 


Leave a comment...

Your Name